{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:30:29Z","timestamp":1788931829887,"version":"build-2803163510"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>\n                    Recurrent or\n                    <jats:italic>de novo<\/jats:italic>\n                    non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH) following liver transplantation (LT) is a frequent event being increasingly recognized over the last decade, but the influence of recurrent NASH on graft and patient outcomes is not yet established. Taking into consideration the long term survival of liver transplanted patients and long term complications with associated morbidity and mortality, it is important to define and minimize risk factors for recurrent NAFLD\/NASH. Metabolic syndrome, obesity, dyslipidemia, diabetes mellitus are life style risk factors that can be potentially modified by various interventions and thus, decrease the risk of recurrent NAFLD\/NASH. On the other hand, genetic factors like recipient and\/or donor PNPLA3, TM6SF2, GCKR, MBOAT7 or ADIPOQ gene polymorphisms proved to be risk factors for recurrent NASH. Personalized interventions to influence the different metabolic disorders occurring after LT in order to minimize the risks, as well as genetic screening of donors and recipients should be performed pre-LT in order to achieve diagnosis and treatment as early as possible.\n                  <\/jats:p>","DOI":"10.3389\/fnut.2021.787430","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T23:32:46Z","timestamp":1642116766000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Genetic and Life Style Risk Factors for Recurrent Non-alcoholic Fatty Liver Disease Following Liver Transplantation"],"prefix":"10.3389","volume":"8","author":[{"given":"Speranta","family":"Iacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Beckebaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan","family":"Iacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Gheorghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Cicinnati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irinel","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Gheorghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jhep.2018.05.011","article-title":"Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies","volume":"69","author":"Pimpin","year":"2018","journal-title":"J Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"106175","DOI":"10.1016\/j.cct.2020.106175","article-title":"The European NAFLD registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease","volume":"98","author":"Hardy","year":"2020","journal-title":"Contemp Clin Trials."},{"key":"B3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1016\/j.clnu.2018.09.019","article-title":"Impact of sarcopenic obesity on outcomes in patients undergoing living donor liver transplantation","volume":"38","author":"Kamo","year":"2019","journal-title":"Clin Nutr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1111\/liv.13876","article-title":"Sarcopenic obesity in cirrhosis \u2013 the confluence of two prognostic titans","volume":"38","author":"Eslamparast","year":"2018","journal-title":"Liver Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1590\/1806-9282.64.02.187","article-title":"Nonalcoholic steatohepatitis in posttransplantation liver: review article","volume":"64","author":"Andrade","year":"2018","journal-title":"Rev Assoc Med Bras"},{"key":"B10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.21037\/tgh.2020.03.02","article-title":"Approach to prevention of non-alcoholic fatty liver disease after liver transplantation","volume":"5","author":"Sharma","year":"2020","journal-title":"Transl Gastroenterol Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/TP.0000000000003681","article-title":"Impact of donor and recipient clinical characteristics and hepatic histology on steatosis\/fibrosis following liver transplantation","volume":"106","author":"Shaked","year":"2022","journal-title":"Transplantation."},{"key":"B12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/lt.25338","article-title":"Predictors of de novo nonalcoholic fatty liver disease after liver transplantation and associated fibrosis","volume":"25","author":"Galvin","year":"2019","journal-title":"Liver Transpl."},{"key":"B13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/MEG.0000000000001105","article-title":"De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients","volume":"30","author":"Gitto","year":"2018","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/lt.23936","article-title":"Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis","volume":"20","author":"Vallin","year":"2014","journal-title":"Liver Transpl."},{"key":"B15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/apt.12881","article-title":"The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US","volume":"40","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/17474124.2019.1551132","article-title":"Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times","volume":"13","author":"Gitto","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"154204","DOI":"10.1016\/j.metabol.2020.154204","article-title":"Post-transplant obesity impacts long-term survival after liver transplantation","volume":"106","author":"van Son","year":"2020","journal-title":"Metabolism."},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.21037\/tgh.2020.02.07","article-title":"Metabolic syndrome following liver transplantation in nonalcoholic steatohepatitis","volume":"6","author":"Spiritos","year":"2021","journal-title":"Transl Gastroenterol Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/lt.23499","article-title":"Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation","volume":"18","author":"Patil","year":"2012","journal-title":"Liver Transpl."},{"key":"B20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/MEG.0000000000000794","article-title":"The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study","volume":"29","author":"Unger","year":"2017","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1097\/TP.0000000000001709","article-title":"Long-term outcomes in patients undergoing liver transplantation for nonalcoholic steatohepatitis-related cirrhosis","volume":"101","author":"Bhati","year":"2017","journal-title":"Transplantation."},{"key":"B22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1432-2277.2012.01576.x","article-title":"Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation","volume":"26","author":"Sprinzl","year":"2013","journal-title":"Transpl Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/lt.24137","article-title":"Cardiovascular disease after liver transplantation. When, what and who is at risk","volume":"21","author":"Fussner","year":"2015","journal-title":"Liver Transpl"},{"key":"B24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrgastro.2015.172","article-title":"Keys to long-term care of the liver transplant recipient","volume":"12","author":"Watt","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/j.1432-2277.2006.00379.x","article-title":"Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial","volume":"19","author":"Cassiman","year":"2006","journal-title":"Transpl Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1002\/hep.31595","article-title":"Pharmacotherapy for weight loss in cirrhosis and liver transplantation: translating the data and underused potential","volume":"73","author":"Brown","year":"2021","journal-title":"Hepatology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1097\/TXD.0000000000000971","article-title":"The use of GLP1R. Agonists for the treatment of type 2 diabetes in kidney transplant recipients","volume":"6","author":"Kukla","year":"2020","journal-title":"Transplant Direct"},{"key":"B28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.15403\/jgld-3616","article-title":"Long term follow-up of liver transplant recipients: considerations for non-transplant specialists","volume":"30","author":"Iacob","year":"2021","journal-title":"J Gastrointestin Liver Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.soard.2020.05.012","article-title":"Bariatric surgery before, during, and after liver transplantation: a systematic review and meta-analysis","volume":"16","author":"Lee","year":"2020","journal-title":"Surg Obes Relat Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1194\/jlr.M100392-JLR200","article-title":"Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients","volume":"43","author":"Morrisett","year":"2002","journal-title":"J Lipid Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut."},{"key":"B35","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/17425255.2020.1801634","article-title":"An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins","volume":"16","author":"Hirota","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.3748\/wjg.v26.i21.2740","article-title":"Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management","volume":"26","author":"Berkovic","year":"2020","journal-title":"World J Gastroenterol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.21037\/atm.2018.10.39","article-title":"Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection?","volume":"6","author":"Scheen","year":"2018","journal-title":"Ann Transl Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s11892-019-1269-4","article-title":"Bariatric surgery in the treatment of type 2 diabetes","volume":"19","author":"Affinati","year":"2019","journal-title":"Curr Diab Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2337\/dc15-0575","article-title":"Determinants of diabetes remission and glycemic control after bariatric surgery","volume":"39","author":"Panunzi","year":"2016","journal-title":"Diabetes Care."},{"key":"B41","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/tri.13288","article-title":"Fat and liver transplantation: clinical implications","volume":"31","author":"Vinaixa","year":"2018","journal-title":"Transpl Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"100265","DOI":"10.1016\/j.jhepr.2021.100265","article-title":"Defatting strategies in the current era of liver steatosis","volume":"3","author":"Mazilescu","year":"2021","journal-title":"JHEP Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1111\/j.1600-6143.2012.04288.x","article-title":"Liver defatting: an alternative approach to enable steatotic liver transplantation","volume":"12","author":"Nativ","year":"2012","journal-title":"Am J Transplant"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.cgh.2013.06.025","article-title":"Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis","volume":"11","author":"Finkenstedt","year":"2013","journal-title":"Clin GastroenterolHepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1111\/hepr.12940","article-title":"Effect of PNPLA3 I148M polymorphism on histologically proven non-alcoholic fatty liver disease in liver transplant recipients","volume":"48","author":"Kim","year":"2018","journal-title":"Hepatol Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.dld.2017.12.030","article-title":"Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis.A post-transplant biopsy-based study","volume":"50","author":"Trunecka","year":"2018","journal-title":"Dig Liver Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/TP.0000000000002876","article-title":"Donor PNPLA3 and TM6SF2 variant alleles confer additive risks for graft steatosis after liver transplantation","volume":"104","author":"M\u00edkov\u00e1","year":"2020","journal-title":"Transplantation."},{"key":"B49","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6002\/ect.2018.0070","article-title":"Recipient but not donor adiponectin polymorphisms are associated with early posttransplant hepatic steatosis in patients transplanted for non-nonalcoholic fatty liver disease indications","volume":"16","author":"John","year":"2018","journal-title":"Exp Clin Transpl."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3748\/wjg.v26.i12.1273","article-title":"Importance of genetic polymorphisms in liver transplantation outcomes","volume":"26","author":"Kelava","year":"2020","journal-title":"World J Gastroenterol."},{"key":"B51","first-page":"86","article-title":"TBX21 genotypes predict occurrence of non-alcoholic steatohepatitis following liver transplantation","volume":"30","author":"Iacob","year":"2021","journal-title":"JGLD"},{"key":"B52","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/TP.0b013e3181cc66ca","article-title":"Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients","volume":"89","author":"Beckebaum","year":"2010","journal-title":"Transplantation."},{"key":"B53","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.clinre.2012.11.003","article-title":"Non-invasive assessment of liver graft fibrosis by transient elastography after liver transplantation","volume":"37","author":"Barrault","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"104","DOI":"10.21614\/sgo-26-2-364","article-title":"Impact of sustained virological response on metabolic profile and kidney function in cured HCV liver transplant recipients","volume":"26","author":"Iacob","year":"2021","journal-title":"Surg. Gastroenterol. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/lt.26219","article-title":"Metabolic complications in liver transplantation recipients: how we can optimize long-term survival","volume":"27","author":"Azhie","year":"2021","journal-title":"Liver Transpl."},{"key":"B56","first-page":"215","article-title":"Current immunosuppressive approaches in liver transplantation","volume":"51","author":"Iacob","year":"2009","journal-title":"Panminerva Med."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2021.787430\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T23:32:50Z","timestamp":1642116770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2021.787430\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":56,"alternative-id":["10.3389\/fnut.2021.787430"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2021.787430","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"article-number":"787430"}}